Comprehensive evaluation of cardiovascular efficacy and safety outcomes of SGLT2 inhibitors in high risk patients of cardiovascular disease: systematic review and meta-analysis

OBJECTIVES: To demonstrate a magnitude of the cardiovascular benefits, concomitantly analyzing the safety outcomes of sodium-glucose cotransporter 2 inhibitor (SGLT2-I) comprehensively, as a class effect in a larger sample size combined from recent randomized control trials. METHODS: We searched ele...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cardiovasc Endocrinol Metab
Egile Nagusiak: Bhattarai, Mukul, Salih, Mohsin, Regmi, Manjari, Al-akchar, Mohammad, Koester, Cameron, Ibrahim, Abdisamad, Parajuli, Priyanka, Garcia, Odalys Lara, Bhandari, Bishal, Rehman, Anis, Siddique, Momin
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Wolters Kluwer Health 2020
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8186520/
https://ncbi.nlm.nih.gov/pubmed/34113794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/XCE.0000000000000229
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak